首页> 外文期刊>World Journal of Gastroenterology >Hepatocellular carcinoma in Egypt: A single center study over a decade.
【24h】

Hepatocellular carcinoma in Egypt: A single center study over a decade.

机译:埃及的肝细胞癌:十年来的一项单中心研究。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To identify the trend, possible risk factors and any pattern change of hepatocellular carcinoma (HCC) in Egypt over a decade. METHODS: All HCC patients attending Cairo Liver Center between January 1993 and December 2002, were enrolled in the study. Diagnosis of HCC was based on histopathological examination and/or detection of hepatic focal lesions by two imaging techniques plus alpha-fetoprotein level above 200 ng/mL. The duration of the study was divided into two periods of 5 years each; period I (1993-1997) and period II (1998-2002). Trend, demographic features of patients (age, gender, and residence), risk factors (HBsAg, HCV-Ab, schistosomiasis and others) and pattern of the focal lesions were compared between the two periods. Logistic regression model was fitted to calculate the adjusted odds ratios for the potential risk factors. The population attributable risk percentage was calculated to estimate the proportion of HCC attributed to hepatitis B and C viral infections. RESULTS: Over a decade, 1 328 HCC patients out of 22 450 chronic liver disease (CLD) patients were diagnosed with an overall proportion of 5.9%. The annual proportion of HCC showed a significant rising trend from 4.0% in 1993 to 7.2% in 2002 (P = 0.000). A significant increase in male proportion from 82.5% to 87.6% (P = 0.009); M/F from 5:1 to 7:1 and a slight increase of the predominant age group (40-59 years) from 62.6% to 66.8% (P = 0.387) in periods I and II respectively, reflecting a shift to younger age group. In the bivariate analysis, HCC was significantly higher in rural residents, patients with history of schistoso-miasis and/or blood transfusion. Yet, after adjustment, these variables did not have a significant risk for development of HCC. There was a significant decline of HBsAg from 38.6% to 20.5% (P = 0.000), and a slight increase of HCV-Ab from 85.6% to 87.9% in periods I and II respectively. HBV conferred a higher risk to develop HCC more than HCV in period I (OR 1.9 vs 1.6) and period II (OR 2.7 vs 2.0), butthe relative contribution of HBV for development of HCC declined in period II compared to period I (PAR% 4.2%, 21.32%). At presentation, diagnostic alpha-fetoprotein level (>=200 ng/mL) was demonstrated in 15.6% vs 28.9% and small HCC (<=3 cm) represented 14.9% vs 22.7% (P = 0.0002) in periods I and II respectively. CONCLUSION: Over a decade, there was nearly a twofold increase of the proportion of HCC among CLD patients in Egypt with a significant decline of HBV and slight increase of HCV as risk factors. alpha-Fetoprotein played a limited role in diagnosis of HCC, compared to imaging techniques. Increased detection of small lesions at presentation reflects increased awareness of the condition.
机译:目的:确定十年来埃及的趋势,可能的危险因素以及肝细胞癌(HCC)的任何模式变化。方法:纳入1993年1月至2002年12月期间在开罗肝病中心就诊的所有HCC患者。 HCC的诊断基于组织病理学检查和/或通过两种成像技术加上200 ng / mL以上的甲胎蛋白水平对肝局灶性病变的检测。研究时间分为两个阶段,每个阶段为5年。第一期(1993-1997)和第二期(1998-2002)。在这两个时期之间比较了患者的趋势,人口统计学特征(年龄,性别和居住地),危险因素(HBsAg,HCV-Ab,血吸虫病等)和局灶性病变的模式。使用Logistic回归模型计算潜在风险因素的调整后优势比。计算人群可归因风险百分比,以估计归因于乙肝和丙肝病毒感染的HCC比例。结果:十年来,在22 450例慢性肝病(CLD)患者中,有1 328例HCC患者被诊断出占总比例的5.9%。肝癌的年比例呈显着上升趋势,从1993年的4.0%上升到2002年的7.2%(P = 0.000)。男性比例从82.5%显着增加到87.6%(P = 0.009); M / F从5:1到7:1,主要年龄段(40-59岁)在第一和第二阶段分别从62.6%略微增加到66.8%(P = 0.387),反映了向年轻年龄的转变组。在双变量分析中,农村居民,有血吸虫病和/或输血史的患者的HCC显着较高。然而,调整后,这些变量对肝癌的发生没有显着风险。在第一和第二阶段,HBsAg从38.6%显着下降到20.5%(P = 0.000),HCV-Ab从85.6%轻微上升到87.9%。在第一阶段(OR 1.9 vs 1.6)和第二阶段(OR 2.7 vs 2.0),HBV产生HCC的风险高于HCV,但是与第一阶段相比,II阶段HBV对HCC发生的相对贡献下降了(PAR% 4.2%,21.32%)。在报告中,在阶段I和阶段II中,诊断性甲胎蛋白水平(> = 200 ng / mL)的比例分别为15.6%和28.9%,小肝癌(<= 3 cm)的比例分别为14.9%和22.7%(P = 0.0002)。 。结论:在过去的十年中,埃及的CLD患者中HCC的比例几乎增加了两倍,其中HBV显着下降,而HCV略有增加是危险因素。与影像技术相比,甲胎蛋白在肝癌的诊断中起着有限的作用。呈现时对小病变的检测增加反映出对该病的认识增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号